• Rss
  • Print

Julio Montaner

Advisory Board

Dr. Montaner is originally from Buenos Aires, Argentina.  He received his Medical Degree with Honors from the University of Buenos Aires in 1979.  In 1981, Dr. Montaner joined the University of British Columbia (UBC) at St Paul’s Hospital (SPH) where he completed his training in Internal Medicine and Respiratory Medicine.  While still in training, Dr. Montaner led several clinical studies that demonstrated the role of adjunctive corticosteroids in PCP-related respiratory failure.  In 1988, he became the Director of the AIDS Research Program and the Immunodeficiency Clinic at SPH/UBC. Since then, he focused his research in the development of antiretroviral therapies and management strategies.  In the mid 90’s, he played a key role in establishing the efficacy of NNRTI based highly active antiretroviral therapy (HAART).  This was one of the pivotal contributions emerging from the IAS-sponsored Vancouver 1996 International AIDS Conference, of which he was a co-organizer.  NNRTI based HAART has since evolved as the standard of care in HIV disease. Over the last five years he led a worldwide effort to establish the role of "Treatment as Prevention". He also has been active in the evaluation and implementation of strategies to facilitate access to health services by drug users, including harm reduction strategies, supervised injection sites and decriminalization of drug use. He is a Professor of Medicine at UBC and has held the Endowed Chair in AIDS Research at SPH/UBC since 1996.  He is a founding Co-Director of the Canadian HIV Trials Network.  He is the Director of the BC Centre for Excellence in HIV/AIDS.  He has been a member of the International AIDS Society (IAS) since 1988, an elected member of the North American Region since 2002 and the IAS past President (2008-2010).  Dr. Montaner has authored over 350 scientific publications on HIV/AIDS.  His current research interests include HAART as prevention, optimal use of HAART, salvage therapy, new antiretrovirals, as well as hard to reach populations and harm reduction.  He has recently received the inaugural Avant-Garde Award of $2.5 million over 5 years, from the National Institute on Drug Abuse of the National Institutes of Health (NIH), to support his project entitled “Seek and Treat for Optimal Outcomes and Prevention in HIV & AIDS in IDU (STOP HIV/AIDS)”. More recently he secured $48M over five years from the Ministry of Health in the Province of British Columbia to enhance outreach efforts to engage HIV infected hard-to-reach populations in appropriate care.